Literature DB >> 28254346

Persistent inflammation with pedal osteolysis 1year after Charcot neuropathic osteoarthropathy.

David R Sinacore1, Kathryn L Bohnert2, Kirk E Smith3, Mary K Hastings2, Paul K Commean4, David J Gutekunst5, Jeffrey E Johnson6, Fred W Prior3.   

Abstract

AIMS: To determine local and systemic markers of inflammation and bone mineral density (BMD) in the foot and central sites in participants with diabetes mellitus and peripheral neuropathy (DMPN) with and without acute Charcot neuropathic osteoarthropathy (CN).
METHODS: Eighteen participants with DMPN and CN and 19 participants without CN had foot temperature assessments, serum markers of inflammation [C-reactive protein, (CRP) and erythrocyte sedimentation rate, (ESR)] and BMD of the foot, hip and lumbar spine at baseline and 1year follow-up.
RESULTS: CN foot temperature difference was higher compared to DMPN controls at baseline (4.2±1.9°F vs. 1.2±0.9°F, P<0.01) and after 1year (2.9±3.2°F vs. 0.9±1.1°F, P<0.01). Serum inflammatory markers in the CN group were greater at baseline and remained elevated 1year later compared to DMPN controls (CRP, P=0.02, ESR, P=0.03). All pedal bones' BMD decreased an average of 3% in the CN foot with no changes in hip or lumbar spine. DMPN controls' foot, hip and lumbar spine BMD remained unchanged.
CONCLUSIONS: Local and systemic inflammation persists 1 year after CN with an accompanying pedal osteolysis that may contribute to mid foot deformity which is the hallmark of the chronic Charcot foot.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone mineral density; Charcot foot; Foot deformity; Inflammatory osteolysis; Skin temperature

Mesh:

Year:  2017        PMID: 28254346      PMCID: PMC5438890          DOI: 10.1016/j.jdiacomp.2017.02.005

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  30 in total

1.  Assessment of technical and biological parameters of volumetric quantitative computed tomography of the foot: a phantom study.

Authors:  K E Smith; B R Whiting; G G Reiker; P K Commean; D R Sinacore; F W Prior
Journal:  Osteoporos Int       Date:  2011-12-07       Impact factor: 4.507

2.  Inflammatory osteolysis in diabetic neuropathic (charcot) arthropathies of the foot.

Authors:  David R Sinacore; Mary K Hastings; Kathryn L Bohnert; Faye A Fielder; Dennis T Villareal; Vilray P Blair; Jeffrey E Johnson
Journal:  Phys Ther       Date:  2008-09-18

3.  Volumetric quantitative computed tomography measurement precision for volumes and densities of tarsal and metatarsal bones.

Authors:  Paul K Commean; Jared A Kennedy; Karen A Bahow; Charles F Hildebolt; Lu Liu; Kirk E Smith; Mary K Hastings; Tao Ju; Fred W Prior; David R Sinacore
Journal:  J Clin Densitom       Date:  2011-07-01       Impact factor: 2.617

4.  Reliability of a diabetic foot evaluation.

Authors:  J E Diamond; M J Mueller; A Delitto; D R Sinacore
Journal:  Phys Ther       Date:  1989-10

5.  Pedal bone density, strength, orientation, and plantar loads preceding incipient metatarsal fracture after charcot neuroarthropathy: 2 case reports.

Authors:  David J Gutekunst; David R Sinacore
Journal:  J Orthop Sports Phys Ther       Date:  2013-09-09       Impact factor: 4.751

6.  Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration.

Authors:  D G Armstrong; L A Lavery; S A Vela; T L Quebedeaux; J G Fleischli
Journal:  Arch Intern Med       Date:  1998-02-09

7.  Long-term follow-up in diabetic Charcot feet with spontaneous onset.

Authors:  J Fabrin; K Larsen; P E Holstein
Journal:  Diabetes Care       Date:  2000-06       Impact factor: 19.112

8.  Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density.

Authors:  S A Herbst; K B Jones; C L Saltzman
Journal:  J Bone Joint Surg Br       Date:  2004-04

9.  A new natural history of Charcot foot: clinical evolution and final outcome of stage 0 Charcot neuroarthropathy in a tertiary referral diabetic foot clinic.

Authors:  Valeria Ruotolo; Barbara Di Pietro; Laura Giurato; Salvatore Masala; Marco Meloni; Orazio Schillaci; Alberto Bergamini; Luigi Uccioli
Journal:  Clin Nucl Med       Date:  2013-07       Impact factor: 7.794

10.  Impact of Charcot neuroarthropathy on metatarsal bone mineral density and geometric strength indices.

Authors:  David J Gutekunst; Kirk E Smith; Paul K Commean; Kathryn L Bohnert; Fred W Prior; David R Sinacore
Journal:  Bone       Date:  2012-10-29       Impact factor: 4.398

View more
  5 in total

1.  A Candidate Imaging Marker for Early Detection of Charcot Neuroarthropathy.

Authors:  Paul K Commean; Kirk E Smith; Charles F Hildebolt; Kathryn L Bohnert; David R Sinacore; Fred W Prior
Journal:  J Clin Densitom       Date:  2017-06-28       Impact factor: 2.617

2.  Immobilization-induced osteolysis and recovery in neuropathic foot impairments.

Authors:  David R Sinacore; Mary K Hastings; Kathryn L Bohnert; Michael J Strube; David J Gutekunst; Jeffrey E Johnson
Journal:  Bone       Date:  2017-09-20       Impact factor: 4.398

3.  Accelerated Cortical Osteolysis of Metatarsals in Charcot Neuroarthropathy: A Cross-Sectional Observational Study.

Authors:  David R Sinacore; Kirk E Smith; Kathryn L Bohnert; David J Gutekunst; Jeffrey E Johnson; Michael J Strube
Journal:  JBMR Plus       Date:  2019-11-05

Review 4.  Pathogenesis and potential relative risk factors of diabetic neuropathic osteoarthropathy.

Authors:  Hong-Mou Zhao; Jia-Yu Diao; Xiao-Jun Liang; Feng Zhang; Ding-Jun Hao
Journal:  J Orthop Surg Res       Date:  2017-10-02       Impact factor: 2.359

5.  Multi-System Factors Associated with Metatarsophalangeal Joint Deformity in Individuals with Type 2 Diabetes.

Authors:  Jennifer A Zellers; Michael J Mueller; Paul K Commean; Ling Chen; Hyo-Jung Jeong; Mary K Hastings
Journal:  J Clin Med       Date:  2020-04-03       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.